Introduction {#sec1-1}
============

Hemangiomas (HAs) are benign neoplasms of the vasculature, and these lesions, often referred to as infantile HAs, are considered to be the most common tumors of infancy. It is estimated that one in every ten children develops HAs, most of which are on the head or neck.^[@ref1]^ Currently, one of the urgent tasks is to discover the molecular mechanisms involved in the development of HAs as well as the reliable biomarkers and possible therapeutic targets.^[@ref2]^

Vascular endothelial growth factors (VEGFs) belong to the platelet-derived growth factor supergene family, and play central roles in the regulation of angiogenesis. Its receptor vascular endothelial growth factor receptor-2 (VEGFR-2) exhibits a strong tyrosine kinase activity towards pro-angiogenic signals, and regulates endothelial cell proliferation, migration, vascular permeability, secretion and other endothelial functions.^[@ref3]^ Some studies have shown that, VEGF and VEGFR2 are highly expressed in invasive breast cancer, and can predict the unfavorable survival of patients.^[@ref4]^ Also, VEGFR-2 polymorphisms can be considered as the prognostic marker for tumor recurrence and overall survival in non-small-cell lung cancer (NSCLC).^[@ref5]^ Moreover, activation of VEGFR2 by VEGF may be important signaling mechanisms involved in the progression and subsequent metastatic spread of prostate cancer.^[@ref6]^ VEGF protein can act on MMP-2, -7 and -9 via its receptor to strengthen cell invasion ability in colon cancer.^[@ref7]^ Therefore, some therapeutic approaches using anti-VEGF/VEGFR2 can be made to inhibit proliferation and induce apoptosis of malignant cells in hematologic diseases.^[@ref8]^

HAs are tumors formed by hyper-proliferation of vascular endothelial cells, which is caused by elevated VEGF signaling through VEGFR2.^[@ref9]^ VEGFR2 gene (KDR) mutation is detected in Juvenile Has tissue but not in adjacent normal tissue, suggesting that one potential mechanism involved in HA formation is the alteration of the VEGF/VEGFR2 signaling pathway in endothelial cells.^[@ref10]^ Some studies have found that VEGFR2 expression is increased in HA patients, and contribute to the formation of the vascular tumors.^[@ref11]^ Interestingly, the proliferative phase of HAs is the result of constitutively high levels of VEGF-dependent signaling through VEGFR2,^[@ref12]^ and VEGFR2 antibody can suppress the activity of VEGF through blocking the VEGFR2 signaling pathways including downstream AKT and ERK pathways, indicating the potential applications of anti-VEGFR2 antibody in the treatment of Has.^[@ref13]^ However, some studies give the opposite view that the levels of serum soluble VEGFR2 are slightly lower in proliferating phase HA patients compared to involuting phase ones, indicating the possible dysregulation of VEGFR2 receptor,^[@ref14]^ while VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex in glioblastoma multiforme.^[@ref15]^ Thus, it is indispensable to further explore the function of VEGF/VEGFR2 signaling in cancer. In the present study, we studied the expression levels of VEGF and VEGFR2 in different phases of human HA. Through shRNA-mediated VEGFR2 knockdown in primary HemECs, we observed the changes of the biological behaviors of the HemECs cells.

Importantly, some studies have reported that AKT and ERK signaling pathways are involved in the pathogenesis of canine haemangiomas^[@ref16]^ and cerebral cavernous malformation.^[@ref17]^ Blockade of these pathways may suppress cell proliferation and induce apoptosis and cycle arrest in proliferative phase HemECs.^[@ref18]^ VEGF/VEGFR2 signaling can be indirectly implicated in endothelial cell growth in proliferating infantile HemECs,^[@ref19]^ and tumor angiogenesis via regulation of AKT and ERK pathways.^[@ref20]^

Whether VEGFR2 directly regulates AKT and ERK pathways in HemECs need to be further explored.

Materials and Methods {#sec1-2}
=====================

Materials {#sec2-1}
---------

The primary HemECs used in the experiments was from Institute of Biochemistry and Cell Biology (Shanghai, China). The lentivirus vector Lv-shVEGFR2/Lv-VEGFR2, negative control vector and virion-packaging elements were from Genechem (Shanghai, China). The primer of VEGF2R was synthesized by ABI (USA). All antibodies were from Santa Cruz Biotechnology (Dallas, TX, USA).

Drugs and reagents {#sec2-2}
------------------

Delphinidin (\>98% pure), a VEGFR2 inhibitor was obtained from Extrasynthase (Lyon, France). Dulbecco's Modified Eagle medium (DMEM) and fetal bovine serum (FBS) were from Thermo Fisher Scientific Inc (Waltham, MA, USA); TRIzol Reagent and Lipofectamine 2000 were from Invitrogen (Carlsbad, CA, USA); M-MLV Reverse Transcriptase was from Promega (Madison, WI, USA); SYBR Green Master Mixture was from Takara (Otsu, Japan). ECL-PLUS/Kit was from GE Healthcare (Piscataway, NJ, USA). Cell apoptosis kit \[Propidium Iodide (PI), RNase A, Annexin V-FITC\] was from KeyGEN biology (Nanjing, China).

Tissue samples {#sec2-3}
--------------

Fifty-five freshly resected human HA samples were collected from Department of General Surgery Affiliated with Xinhua Hospital, and were classified according to International Society for the Study on Vascular Anomalies (ISSVA) criteria. Tissues and clinical information were summarized in [Table 1](#table001){ref-type="table"} and obtained as part of an approved study at Shanghai Jiao Tong University School of Medicine. There were 30 cases of proliferating phase HAs and 25 cases of involuting phase HAs. A portion of each tissue sample was fixed with 10% formalin for histopathological and IHC examination. All HA tissues were diagnosed by two independent pathologists.

Immunohistochemical staining {#sec2-4}
----------------------------

Tissue microarray sections were processed for immunohistochemical (IHC) analysis of VEGF, VEGFR2, Ki-67, Glut-1, p-AKT and p-ERK proteins as follows. Immunohistochemical examinations were carried out on 3 mm thick sections. For anti-VEGF, VEGFR2, Ki-67, Glut-1, p-AKT and p-ERK immunohistochemistry, unmasking was performed with 10 mM sodium citrate buffer, pH 6.0, at 90°C for 30 min. For anti-VEGF, VEGFR2, Ki-67, Glut-1, p-AKT and p-ERK immunohistochemistry, antigen unmasking was not necessary. Sections were incubated in 0.03% hydrogen peroxide for 10 min at room temperature, to remove endogenous per-oxidase activity, and then in blocking serum (0.04% bovine serum albumin, A2153, Sigma-Aldrich, Shanghai, China; and 0.5% normal goat serum X0907, Dako Corporation, Carpinteria, CA, USA, in PBS) for 30 min at room temperature. Anti-VEGF and VEGFR2, Ki-67, Glut-1, p-AKT and p-ERK antibodies were used at a dilution of 1:200. The antibody was incubated overnight at 4°C. Sections were then washed three times for 5 min in PBS. Non-specific staining was blocked with 0.5% casein and 5% normal serum for 30 min at room temperature. Finally, staining was developed using diaminobenzidine substrate, and sections were counterstained with hematoxylin. Normal serum or PBS was used to replace anti-VEGF, VEGFR2, Ki-67, Glut-1, p-AKT and p-ERK antibodies in negative controls. The expression of VEGF, VEGFR2, Ki-67, Glut-1, p-AKT and p-ERK was semiquantitatively estimated as the total IHC staining score, which was calculated as the sum of a proportion score. The score reflected the fraction of positive staining cells ( -, \<5%; +, 5% 25%; ++, \>25% 50%; +++, \>50%).

TUNEL assay {#sec2-5}
-----------

Apoptosis was detected by the TdT-mediated dUTP nick end labeling (TUNEL) method for HA cells (1×10^5^ clones). Briefly, sections were dewaxed, incubated with blocking solution (0.3% H~2~O~2~ in double distilled water) for 30 min, and permeabilized with 0.1% Triton X-100 in PBS for two min on ice. Apoptosis was detected using an in-situ cell death kit (Boehringer Mannheim, Germany). Positive cells were visualized by fluorescence microscopy. As a control, the reaction mixture was incubated without enzyme to detect nonspecific staining. The apoptotic index was calculated from the ratio of the number of positively stained tumor cells to the total number of tumor cells counted per section.

Cell culture and transfection {#sec2-6}
-----------------------------

The proliferating phase HemECs (1×10^5^ clones) was cultured in DMEM medium supplemented with 10% heat-inactivated FBS, 100 U/mL of penicillin and 100 μg/mL of streptomycin. They were all placed in a humidified atmosphere containing 5% CO~2~ at 37°. Lv-shVEGFR2/Lv-VEGFR2 and negative control virus were transfected into proliferating phase HemECs. Cells were subcultured at a 1:5 dilution in medium containing 300 µg/mL G418 (an aminoglycoside antibody, commonly used stable transfection reagent in molecular genetic testing). On the day of transduction, HemECs were replated at 5×10^4^ cells/well in 24-well plates containing serum-free growth medium with polybrene (5 mg/mL). When reached 50% confluence, cells were transfected with recombinant experimental virus or control virus at the optimal MOI (multiplicity of infection) of 50, and cultured at 37°C and 5% CO~2~ for 4 h. Then supernatant was discarded and serum containing growth medium was added. At 4 days of post-transduction, transduction efficiency was measured by the frequency of green fluorescent protein (GFP)-positive cells. The clone in which Lv-shVEGFR2 vectors transfected was named as shVEGFR2 group, the negative control vectors transfected was named as negative control (NC) group. The untreated HemECs was named as control (CON) group.

Quantitative real-time PCR {#sec2-7}
--------------------------

To quantitatively determine the mRNA expression level of VEGFR2 in proliferating phase HemECs (1×10^5^ clones), Real-time PCR was used. Total RNA of each clone was extracted with TRIzol according to the manufacturer's protocol. Reverse-transcription was carried out using M-MLV and cDNA amplification was carried out using SYBR Green Master Mix kit according to the manufacturer's protocol. VEGFR2 gene was amplified using specific oligonucleotide primer and human glyceralde-hyde-3-phosphate dehydrogenase (GAPDH) gene was used as an endogenous control. The PCR primer sequences of VEGFR2 gene were as follows:5'-CTTCGAAGCATCAGCATAAGAAACT-3' and 5'-TGGTCATCAGCCC ACTGGAT-3'; GAPDH, 5'-AACGACCCCTTCATTGAC-3' and 5'-TCCACGAC ATACTCAGCAC-3'. Data were analyzed using the comparative Ct method (2^-ΔΔCt^). Three separate experiments were performed for each clone.

Western blot assay {#sec2-8}
------------------

The proliferating phase HemECs (1×10^5^ clones) was harvested and extracted using lysis buffer (Tris-HCl, SDS, Mercaptoethanol, Glycerol). Cell extracts were boiled for 5 min in loading buffer and then equal amount of cell extracts were separated on 15% SDS-PAGE gels. Separated protein bands were transferred into polyvinylidene fluoride (PVDF) membranes and the membranes were blocked in 5% skim milk powder. The primary antibodies against VEGFR2, p-AKT, p-ERK, p-p38MAPK, Ki-67 and CAS-3 were diluted according to the instructions of antibodies and incubated overnight at 4°C. Then, horseradish peroxidase-linked secondary antibodies were added at a dilution ratio of 1:1000, and incubated at room temperature for 2 h. The membranes were washed with PBS for three times and the immunoreactive bands were visualized using ECL-PLUS/Kit according to the kit's instruction. The relative protein level in HemECs was normalized to β-actin concentration. Three separate experiments were performed for each clone.

Cell viability assay {#sec2-9}
--------------------

Cell viability was analyzed with the MTT assay. Briefly, HemECs infected with Lv-shVEGFR2 or treated with Delphinidin (0, 10 μM, 50 μM) were incubated in 96-well-plates at a density of 1×10^5^ cells per well with DEME medium supplemented with 10% FBS. Cells were treated with 20 μL MTT dye at 0, 24 h, 48 h and 72 h, and then incubated with 150 μL of DMSO for 5 min. The color reaction was measured at 570 nm with enzyme immunoassay analyzer (Bio-Rad, American). The proliferation activity was calculated for each clone.

Cell apoptosis analysis {#sec2-10}
-----------------------

To detect cell apoptosis, the proliferating phase HemECs (1×10^5^ clones) was trypsinized, washed with cold PBS and resuspended in binding buffer according to the instruction of the apoptosis kit. FITC-AnnexinV and PI were added to the fixed cells for 20 min in darkness at room temperature. Then, Annexin V binding buffer was added to the mixture before the fluorescence was measured on FACsort flow cytometer. The cell apoptosis was analyzed using the Cell Quest software (Becton Dickinson, Franklin Lakes, NJ, USA). Three separate experiments were performed for each clone.

Statistical analysis {#sec2-11}
--------------------

SPSS 20.0 was used for the statistical analysis. One-way analysis of variance (ANOVA) was used to analyze the differences between groups. The Fisher's Least Significant Difference (LSD) method of multiple comparisons was used when the probability for ANOVA was statistically significant. Statistical significance was P\<0.05.

Results {#sec1-3}
=======

Expression of VEGF, VEGFR2, Ki-67, Glut-1, p-AKT and p-ERK in human hemangiomas {#sec2-12}
-------------------------------------------------------------------------------

The expression of VEGF, VEGFR2, Ki-67, Glut-1, p-AKT and p-ERK proteins was evaluated using IHC analysis. As shown in [Figure 1 AL](#fig001){ref-type="fig"}, the positive staining of VEGF, VEGFR2, Ki-67, Glut-1, p-AKT and p-ERK proteins was found strong, and was mainly localized in the cytoplasm or cell membrane in proliferating phase HA, but that of these proteins was week in involuting phase HA. As indicated in [Table 2](#table002){ref-type="table"}, the positive rates of VEGF, VEGFR2, Ki-67, Glut-1, p-AKT and p-ERK were significantly higher in proliferating phase HA than those in involuting phase HA (P\<0.01).

Apoptotic index of human hemangioma {#sec2-13}
-----------------------------------

As shown in [Figure 2](#fig002){ref-type="fig"}, using TUNEL method we found that the apoptotic indexes were dramatically decreased in proliferating phase HA, but increased in involuting phase HA. There was a significant difference between these two groups (P\<0.01).

Effect of VEGFR2 knockdown on p-AKT and p-ERK expression {#sec2-14}
--------------------------------------------------------

To examine whether the expression of VEGFR2 was knocked down by Lv-shVEGFR2 in proliferative phase HemECs, the mRNA expression level of VEGFR2 was measured by Real-time PCR ([Figure 3A](#fig003){ref-type="fig"}) An obvious inhibition of VEGFR2 mRNA expression was observed in shVEGFR2 group compared with the NC and CON groups (\*\*P\<0.01). As for the protein expression indicated by Western blot assay ([Figure 3 B-E](#fig003){ref-type="fig"}), VEGFR2, p-AKT, p-ERK and p-p38MAPK were markedly downregulated in shVEGFR2 group in comparison with the NC and CON groups in primary HemECs (\*\*P\<0.01).

Effect of VEGFR2 on cell proliferation {#sec2-15}
--------------------------------------

By comparing the viability assessed by MTT assay among different culture days, the cell proliferative activity was evaluated in primary HemECs, and Ki-67 was used to assess cell proliferation. As a result, knockdown of VEGFR2 significantly diminished proliferative activities of HemECs ([Figure 4A](#fig004){ref-type="fig"}) while overexpression of VEGFR2 enhanced cell viability ([Figure 4B](#fig004){ref-type="fig"}) in a time-dependent manner compared with NC and CON groups. In addition, the expression of Ki-67 protein was examined by Western blot. The amount of Ki-67 protein was significantly decreased in shVEGFR2 group ([Figure 4C](#fig004){ref-type="fig"}), but increased in Lv-VEGFR2 group ([Figure 4D](#fig004){ref-type="fig"}) compared with NC and CON groups (\*\*P\<0.01).

Effect of Delphinidin, a VEGFR2 inhibitor on cell viability {#sec2-16}
-----------------------------------------------------------

The primary HemECs were pretreated with different concentrations of Delphinidin (0, 10 μM, 50 μM), and the expression of VEGF and VEGFR2 was examined by Western blot and cell viability was assessed by MTT assay. It was found that Delphinidin could markedly down-regulate the expression of VEGF and VEGFR2 ([Figure 5 A](#fig005){ref-type="fig"},[B](#fig005){ref-type="fig"}) and reduce cell viability ([Figure 5C](#fig005){ref-type="fig"}) in a dose-dependent manner in primary HemECs.

Effect of VEGFR2 on cell apoptosis {#sec2-17}
----------------------------------

To determine whether VEGFR2 influenced cell apoptosis in primary HemECs, flow cytometric analysis was performed. Cell apoptotic indexes were significantly increased in shVEGFR2 group ([Figure 6 A](#fig006){ref-type="fig"},[B](#fig006){ref-type="fig"}), but was decreased in Lv-VEGFR2 group ([Figure 6 C](#fig006){ref-type="fig"},[D](#fig006){ref-type="fig"}) compared with NC and CON groups (\*\*P\<0.01). In order to determine whether VEGFR2 regulated the expression of CAS-3 through translational level, the expression of CAS-3 protein was examined by Western blot. The amount of CAS-3 protein was significantly increased in shVEGFR2 group ([Figure 6E](#fig006){ref-type="fig"}), but was decreased in Lv-VEGFR2 group ([Figure 6F](#fig006){ref-type="fig"}) compared with NC and CON groups (\*\*P\<0.01).

Discussion {#sec1-4}
==========

VEGF and its receptor VEGFR have been shown to play major roles not only in physiological but also in pathological angiogenesis including HA. The VEGF-VEGFR system is an important target for anti-angiogenic therapy in cancer.^[@ref21]^ Overexpression of VEGF/VEGFR-2 signaling plays an important role in promoting invasion and migration of pancreatic cancer cells,^[@ref22]^ and is associated with the prognosis in patients with lung squamous cell carcinoma.^[@ref23]^ Moreover, VEGFR-2-mediated signal contributes to proliferation of vascular tumor cells,^[@ref24]^ while blockade of this signaling through VEGF inhibitor bevacizumab provides a potential treatment of for hepatic HA.^[@ref25]^

However, soluble VEGFR2 in some studies have been found to be lowly expressed in invasive colorectal cancer,^[@ref26]^ while PVITRO2-hmsVEGFR2, which may be a novel DNA vaccine for the anti-tumor therapy, can inhibit angiogenesis.^[@ref27]^ To understand the role of VEGFR2 signaling in HAs, we examined the expression of VEGF and VEGFR2 in human HA tissue using IHC, and found that, the expression of VEGF, VEGFR2, Ki-67, Glut-1, p-AKT and p-ERK was significantly increased in proliferating phase HAs, but decreased in involuting phase HAs, suggesting VEGFR2 signaling may be implicated in the development of HAs. Furthermore, blockade of the VEGF/VEGFR pathway may be a rational and effective therapy for certain tumor patients including Has.^[@ref28]^ The agents, which can inhibit this signaling transduction, need be identified and confirmed to be beneficial to the patients. Elpamotide is an immunogenic peptide derived from VEGFR2, and inhibits tumor angiogenesis in advanced solid tumors, indicating a potentially valuable approach to cancer.^[@ref29]^ Targeted silencing of VEGFR2 and EGFR expression by siRNA, combined with cisplatin is found to effectively inhibit tumor growth and extend the survival time of NSCLC xenografts.^[@ref30]^ Intriguingly, propranolol markedly inhibits HA and normal endothelial cell function, including cell proliferation, migration, and formation of the cytoskeleton coincident through inhibition of VEGFR2 and p38 signaling.^[@ref31]^ In the present study, our findings showed that, knockdown of VEGFR2 significantly suppressed cell proliferation and induced cell apoptosis, but overexpression of VEGFR2 promoted proliferation and blocked apoptosis in primary HemECs. Importantly, Delphinidin, a VEGFR2 inhibitor could markedly downregulated the expression of VEGF and VEGFR2, and reduce cell viability. Some studies also support our findings, indicating that up-regulation of the autocrine VEGF/VEGFR2 loop induces general resistance to apoptotic stimuli in HemECs.^[@ref32]^ These reports suggest that, VEGFR2 signaling might promote the progression of HAs, and represent a novel therapeutic target.

There is growing evidence that activation of AKT and ERK pathways plays a significant role in cancer, and offers targeted therapy approaches for cancer.^[@ref33]^ Bevacizumab inhibits tumor growth and attenuates VEGFR2-induced p-AKT and p-ERK,^[@ref34]^ and usnic acid^[@ref35]^ or luteolin^[@ref36]^ also suppresses tumor angiogenesis and growth by suppressing VEGFR2-mediated ERK and AKT signaling pathways. More importantly, inhibition of HA development in a syngeneic mouse model correlates with the inhibition of AKT and ERK activity.^[@ref37]^ In the present study, we found that, knockdown of VEGFR2 could significantly downregulate the expression of p-AKT, p-ERK, and p-p38MAPK in primary HemECs, suggesting that VEGFR2 signaling may be implicated in HA proliferation and inhibition of apoptosis via regulation of the AKT, ERK and MAPK signaling pathways.

Many studies have proved that Ki-67 can be used as the biomarker of the tumor in response to cellular proliferation. It also serves as a diagnostic tool to distinguish between benign and malignant vascular lesions including Has.^[@ref38]^ In addition, CAS-3 is also involved in the development of HAs, and promotes the switch of HAs from proliferation to involution by inducing the apoptosis of HAs endothelia.^[@ref39]^ AKT, ERK and MAPK signaling pathways have been found to be correlated with the expression of Ki-67 in human cancers.^[@ref40]^ In the present study, we also found that, knockdown of VEGFR2 could significantly downregulate the expression of Ki-67, and upregulate the expression of CAS-3 in primary HemECs, suggesting that AKT, ERK and MAPK pathways might mediate the effects of VEGFR2 on HAs through regulation of expression of Ki-67 and CAS-3.

In conclusion, our findings indicate that the expression of VEGF and VEGFR2 is significantly elevated in proliferating phase HAs, but decreased in involuting phase HAs. Knockdown of VEGFR2 inhibits proliferation and induces cell apoptosis, but overexpression of VEGFR2 promotes proliferation and blocks apoptosis in primary HemECs possibly through regulation of the AKT and ERK pathways, suggesting that VEGFR2 may be a potential therapeutic target for the treatment of human hemangioma.

![Expression of VEGF, VEGFR2, Ki-67, Glut-1, p-AKT and p-ERK in human HAs (×400). The positive expression of these proteins, mainly localized in the cytoplasm or cell membrane, was strong in proliferating phase HAs, but week in involuting phase HA. A, C, E, G, I, K) Expression of VEGF, VEGFR2, Ki-67, Glut-1, p-AKT and p-ERK, respectively, in proliferating phase HAs. B, D, F, H, J, L) Expression of VEGF, VEGFR2, Ki-67, Glut-1; J), p-AKT and p-ERK, respectively, in involuting phase Has. Scale bars: 37.5 µm.](ejh-2014-1-2263-g001){#fig001}

![Apoptotic indexes of human HAs examined by TUNEL assay (×400). A) Positive staining of apoptotic cells in involuting phase Has. B) Positive staining of apoptotic cells in proliferating phase Has. C) The apoptotic cells were dramatically decreased in proliferating phase HAs, but increased in involuting phase HAs (P\<0.01). Scale bars: 37.5 µm.](ejh-2014-1-2263-g002){#fig002}

![Effect of VEGFR2 on p-AKT. p-ERK and p-p38MAPK expression in primary HemECs. A) Expression level of VEGFR2 mRNA was reduced in shVEGFR2 group compared with CON and NC groups (\*\*P\<0.01). B,C) Expression of VEGFR2 protein was markedly downregulated in shVEGFR2 group compared with CON and NC groups (\*\*P\<0.01). D,E) Expression of p-AKT, p-ERK and p-p38MAPK was also downregulated in shVEGFR2 group compared with CON and NC groups (\*\*P\<0.01).](ejh-2014-1-2263-g003){#fig003}

![Effect of VEGFR2 on cell viability. A) Knockdown of VEGFR2 significantly diminished cell viability. B) Overexpression of VEGFR2 promoted proliferation in a time-dependent manner in HemECs (\*\*P\<0.01). C) Protein expression of Ki-67 was significantly decreased in shVEGFR2 group. D) Expression of Ki-67 was increased in Lv-VEGFR2 group compared with CON and NC groups (\*\*P\<0.01).](ejh-2014-1-2263-g004){#fig004}

![Effect of Delphinidin on cell proliferation. A, B) Delphinidin suppressed the protein expression levels of VEGF and VEGFR2 and cell viability (C) in a dose-dependent manner in primary HemECs (\*\*P\<0.01).](ejh-2014-1-2263-g005){#fig005}

![Effect of VEGFR2 on cell apoptosis. A, B) Flow cytometric analysis showed that cell apoptotic indexes of HemECs were increased in shVEGFR2 group, but were decreased in Lv-VEGFR2 group (C, D) compared with CON and NC groups (\*\*P\<0.01). E) The protein expression of CAS-3 was upregulated in shVEGFR2 group, but downregulated in Lv-VEGFR2 group (F) compared with CON and NC groups (\*\*P\<0.01).](ejh-2014-1-2263-g006){#fig006}

###### 

Clinicopathologic characteristics of hemangioma patients.

  Variables               Number of cases
  ----------------------- -----------------
  Number of patients      55 (100%)
  Age (yrs)               
    ≥1                    32 (58.2%)
    1                     23 (41.8%)
  Gender                  
    Male                  25 (45.5%)
    Female                30 (54.5%)
  Location                
    Head and neck         34 (61.8%)
    Trunk and limbs       21 (38.2%)
  Treatment               
    Yes                   0 (0%)
    No                    55 (100%)
  Classification          
    Proliferating phase   30 (54.5%)
    Involuting phase      25 (45.5%)

###### 

Expression of VEGF, VEGFR2, Ki-67, Glut-1, p-AKT and p-ERK in human hemangiomas.

  Target                 Group                     Cases   n    Positive rate (%)   *X*^2^   P                      
  ---------------------- ------------------------- ------- ---- ------------------- -------- ------ ------ -------- ---------
  VEGF                   Proliferating phase HAs   30      6    7                   12       5      80.0   11.712   0.001
  Involuting phase HAs   25                        13      9    3                   0        48.0                   
  VEGFR2                 Proliferating phase HAs   30      8    6                   10       6      73.3   8.628    0.003
  Involuting phase HAs   25                        15      6    3                   1        40.0                   
  Ki-67                  Proliferating phase HAs   30      7    12                  6        5      76.7   5.559    0.018
  Involuting phase HAs   25                        14      6    4                   1        44.0                   
  Glut-1                 Proliferating phase HAs   30      5    8                   8        9      83.3   19.921   \<0.001
  Involuting phase HAs   25                        18      5    2                   0        28.0                   
  p-AKT                  Proliferating phase HAs   30      8    13                  7        2      73.3   8.512    0.004
  Involuting phase HAs   25                        16      7    2                   0        36.0                   
  p-ERK                  Proliferating phase HAs   30      10   13                  5        2      66.7   8.913    0.003
  Involuting phase HAs   25                        18      6    1                   0        28.0                   

Has, hemangiomas.
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